Genesis Research Group names Vera Frajzyngier to lead real-world evidence

Genesis Research Group has appointed Vera Frajzyngier, PhD, as vice president and head of real-world evidence, expanding the company’s leadership bench as it pushes integrated evidence strategies across development and commercialization. Frajzyngier brings more than 20 years of experience in scientific consulting, biopharma, and global health research.

Why it matters: - Genesis Research Group is adding a senior leader as demand grows for real-world evidence that can support development, market access, and commercialization decisions. - Frajzyngier’s background spans regulatory-grade evidence generation, pharmacoepidemiology, and cross-functional scientific leadership. - The hire strengthens Genesis Research Group’s ability to connect real-world evidence with HEOR, evidence synthesis, market access, and stakeholder insight.

What happened: - Genesis Research Group appointed Vera Frajzyngier, PhD, as vice president, head of real-world evidence. - Frajzyngier will report to Sarah Alwardt, PhD, executive vice president, RWE/HEOR. - Frajzyngier will lead Genesis Research Group’s global RWE business. - The role is designed to further strengthen integrated evidence strategies across development and commercialization.

The details: - Frajzyngier most recently served as vice president and group head of regulatory RWE and pregnancy at Datavant. - At Datavant, she led scientific teams delivering regulatory-grade real-world evidence and pharmacoepidemiology studies for life sciences organizations. - Earlier in her career, Frajzyngier spent nearly a decade in epidemiology divisions within the pharmaceutical industry. - Her prior employers included Pfizer and Boehringer Ingelheim. - Her work has covered product development, regulatory decision-making, safety evaluation, and post-marketing evidence needs. - Frajzyngier has led global scientific teams and advised on regulatory engagements. - Her therapeutic area experience includes immunology, oncology, vaccines, infectious disease, hepatology, dermatology, and rare diseases. - She also led epidemiologic research initiatives in the not-for-profit sector in the U.S. and internationally. - Frajzyngier served as an adjunct professor of pharmacoepidemiology at Tulane University School of Public Health and Tropical Medicine and Baruch College. - She holds a PhD in Epidemiology from Columbia University.

Between the lines: - Sarah Alwardt said Frajzyngier brings a perspective that reflects the decisions clients are trying to make and a track record of building scientific teams and delivering high-quality evidence programs. - Frajzyngier said Genesis stood out because it combines scientific depth with a broader strategic view of how evidence supports decision-making. - Her comments suggest Genesis is positioning RWE as part of a broader advisory offering, not a stand-alone analytics service.

What's next: - Frajzyngier will help Genesis Research Group expand evidence strategies that align scientific rigor with regulatory, access, and commercialization priorities. - Her leadership is likely to support the company’s continued integration of RWE with HEOR and related evidence services. - Genesis Research Group did not announce additional personnel changes or a timeline for new programs in the release.

The bottom line: - Genesis Research Group is betting that deeper RWE leadership will help clients move faster and make stronger evidence-based decisions across the product lifecycle.